The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting

References

• Horowitz M. Uses and growth of hematopoietic cell transplantation. Hematopoietic Cell Transplantation, K G Blumex, S J Forman, F R Applebaum. Wiley Blackwell Publishing, Hoboken, NJ 2004
   Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Levine J E, Harris R E, Loberiza F R, Jr, Armitage J O, Vose J M, Van Besien K, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476–2482
   PubMed Web of Science ®Google Scholar
• Zhang M J, Hoelzer D, Horowitz M M, Gale R P, Messerer D, Klein J P, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The acute lymphoblastic leukemia working committee. Ann Intern Med 1995; 123: 428–431
   PubMed Web of Science ®Google Scholar
• Zittoun R A, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European organization for research and treatment of cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) leukemia cooperative groups. N Engl J Med 1995; 332: 217–223
   PubMed Web of Science ®Google Scholar
• Wysocki C A, Panoskaltsis-Mortari A, Blazar B R, Serody J S. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191–4199
   PubMed Web of Science ®Google Scholar
• Goker H, Haznedaroglu I C, Chao N J. Acute graft-vs.-host disease: pathobiology and management. Exp Hematol 2001; 29: 259–277
   PubMed Web of Science ®Google Scholar
• Higman M A, Vogelsang G B. Chronic graft versus host disease. Br J Haematol 2004; 125: 435–454
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei K J, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–1886
   PubMed Web of Science ®Google Scholar
• Fantini M C, Becker C, Monteleone G, Pallone F, Galle P R, Neurath M F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172: 5149–5153
   PubMed Web of Science ®Google Scholar
• Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, et al. CD8+ CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323–4334
   PubMed Web of Science ®Google Scholar
• Najafian N, Chitnis T, Salama A D, Zhu B, Benou C, Yuan X, et al. Regulatory functions of CD8+CD28-T cells in an autoimmune disease model. J Clin Invest 2003; 112: 1037–1048
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53–65
   PubMed Web of Science ®Google Scholar
• Gershon R K, Kondo K. Infectious immunological tolerance. Immunology 1971; 21: 903–914
   PubMed Web of Science ®Google Scholar
• Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969; 166: 753–755
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161: 72–87
   Google Scholar
• Smith H, Sakamoto Y, Kasai K, Tung K S. Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy. J Immunol 1991; 147: 2928–2933
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–1164
   PubMed Web of Science ®Google Scholar
• Herbelin A, Gombert J M, Lepault F, Bach J F, Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing l-selectin mediate “active tolerance” in the nonobese diabetic mouse. J Immunol 1998; 161: 2620–2628
   PubMed Web of Science ®Google Scholar
• McHugh R S, Whitters M J, Piccirillo C A, Young D A, Shevach E M, Collins M, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311–323
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135–142
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303–310
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen K J, Boden E K, Tooley A J, Ye J, Subudhi S K, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 3348–3352
   PubMed Web of Science ®Google Scholar
• Godfrey V L, Wilkinson J E, Russell L B. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991; 138: 1379–1387
   PubMed Web of Science ®Google Scholar
• Wildin R S, Smyk-Pearson S, Filipovich A H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39: 537–545
   PubMed Web of Science ®Google Scholar
• Bennett C L, Christie J, Ramsdell F, Brunkow M E, Ferguson P J, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20–21
   PubMed Web of Science ®Google Scholar
• Brunkow M E, Jeffery E W, Hjerrild K A, Paeper B, Clark L B, Yasayko S A, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68–73
   PubMed Web of Science ®Google Scholar
• Chatila T A, Blaeser F, Ho N, Lederman H M, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. J Clin Invest 2000; 106: R75–R81
   PubMed Web of Science ®Google Scholar
• Fontenot J D, Gavin M A, Rudensky A Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330–336
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061
   PubMed Web of Science ®Google Scholar
• Khattri R, Cox T, Yasayko S A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337–342
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen K J, Bi M, Finger E B, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 1455–1465
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam A L, Xu-Yu Z, Szot G L, Lee M R, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701–1711
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)- 2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693–1700
   PubMed Web of Science ®Google Scholar
• Thornton A M, Shevach E M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287–296
   PubMed Web of Science ®Google Scholar
• Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538–1543
   PubMed Web of Science ®Google Scholar
• Piccirillo C A, Shevach E M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167: 1137–1140
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, Fathman C G, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399
   PubMed Web of Science ®Google Scholar
• Asseman C, Mauze S, Leach M W, Coffman R L, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995–1004
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202: 1075–1085
   PubMed Web of Science ®Google Scholar
• Grossman W J, Verbsky J W, Barchet W, Colonna M, Atkinson J P, Ley T J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589–601
   PubMed Web of Science ®Google Scholar
• Taylor P A, Lees C J, Blazar B R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493–3499
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C G, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150
   PubMed Web of Science ®Google Scholar
• Johnson B D, Konkol M C, Truitt R L. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525–535
   PubMed Web of Science ®Google Scholar
• Jones S C, Murphy G F, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003; 9: 243–256
   PubMed Web of Science ®Google Scholar
• Taylor P A, Panoskaltsis-Mortari A, Swedin J M, Lucas P J, Gress R E, Levine B L, et al. l-selectin(hi) but not the l-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104: 3804–3812
   PubMed Web of Science ®Google Scholar
• Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon B L, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112: 1688–1696
   PubMed Web of Science ®Google Scholar
• Chai J G, Coe D, Chen D, Simpson E, Dyson J, Scott D. In vitro expansion improves in vivo regulation by CD4+ CD25+ regulatory T cells. J Immunol 2008; 180: 858–869
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Kunz-Schughart L A, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104: 895–903
   PubMed Web of Science ®Google Scholar
• Nguyen V H, Zeiser R, Dasilva D L, Chang D S, Beilnack A, Contag C H, Negrin R S. In vivo dynamics of regulatory T cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109: 2649–2656
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhao Z C, Yi T, Lin C, Todorov I, Kandeel F, et al. In vivo activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic GVHD. Blood 2007; 110: 110a
   Web of Science ®Google Scholar
• Jacobsohn D A, Vogelsang G B. Acute graft versus host disease. Orphanet J Rare Dis 2007; 2: 35
   PubMed Web of Science ®Google Scholar
• Shlomchik W D. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340–352
   PubMed Web of Science ®Google Scholar
• Hanash A M, Levy R B. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005; 105: 1828–1836
   PubMed Web of Science ®Google Scholar
• Barao I, Hanash A M, Hallett W, Welniak L A, Sun K, Redelman D, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103: 5460–5465
   PubMed Web of Science ®Google Scholar
• Szanya V, Ermann J, Taylor C, Holness C, Fathman C G. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses l-selectin and high levels of CCR7. J Immunol 2002; 169: 2461–2465
   PubMed Web of Science ®Google Scholar
• Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg F G, Higgins J P, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220–2226
   PubMed Web of Science ®Google Scholar
• Carlson M J, Seidel H E, Serody J S. CD62L is not critical for T-Regulatory cell-mediated protection from lethal acute GVHD. American Society of Hematology, Atlanta, GA 2007, Poster board #368-II
   Google Scholar
• Wysocki C A, Jiang Q, Panoskaltsis-Mortari A, Taylor P A, McKinnon K P, Su L, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 3300–3307
   PubMed Web of Science ®Google Scholar
• Varona R, Cadenas V, Lozano M, Moreno-Ortiz M C, Kremer L, Martinez A C, et al. CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease. Leuk Lymphoma 2006; 47: 1469–1476
   PubMed Web of Science ®Google Scholar
• Mielke S, Rezvani K, Savani B N, Nunes R, Yong A S, Schindler J, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110: 1689–1697
   PubMed Web of Science ®Google Scholar
• Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472–479
   PubMed Web of Science ®Google Scholar
• Davison G M, Novitzky N, Kline A, Thomas V, Abrahams L, Hale G, et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341–1347
   PubMed Web of Science ®Google Scholar
• Clark F J, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103: 2410–2416
   PubMed Web of Science ®Google Scholar
• Miura Y, Thoburn C J, Bright E C, Phelps M L, Shin T, Matsui E C, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004; 104: 2187–2193
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim H T, Lee S J, Floyd B H, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903–2911
   PubMed Web of Science ®Google Scholar
• Sanchez J, Casano J, Alvarez M A, Roman-Gomez J, Martin C, Martinez F, et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697–703
   PubMed Web of Science ®Google Scholar
• Schneider M, Munder M, Karakhanova S, Ho A D, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol 2006; 28: 382–390
   PubMedGoogle Scholar
• Wolf D, Wolf A M, Fong D, Rumpold H, Strasak A, Clausen J, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007; 83: 1107–1113
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, Endl E, Weihrauch M R, Knolle P A, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940–3949
   PubMed Web of Science ®Google Scholar
• Curiel T J, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Liyanage U K, Moore T T, Joo H G, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–2761
   PubMed Web of Science ®Google Scholar
• Marshall N A, Christie L E, Munro L R, Culligan D J, Johnston P W, Barker R N, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755–1762
   PubMed Web of Science ®Google Scholar
• Wolf A M, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606–612
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf A M, Rumpold H, Fiegl H, Zeimet A G, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326–8331
   PubMed Web of Science ®Google Scholar
• Woo E Y, Chu C S, Goletz T J, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766–4772
   PubMed Web of Science ®Google Scholar